Free Trial
NASDAQ:PRFX

PainReform (PRFX) Stock Price, News & Analysis

$0.50
-0.02 (-3.81%)
(As of 07/19/2024 ET)
Today's Range
$0.51
$0.54
50-Day Range
$0.46
$0.85
52-Week Range
$0.43
$11.37
Volume
22,723 shs
Average Volume
131,596 shs
Market Capitalization
$1.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

PainReform MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
296.0% Upside
$2.00 Price Target
Short Interest
Healthy
2.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

PRFX stock logo

About PainReform Stock (NASDAQ:PRFX)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX Stock Price History

PRFX Stock News Headlines

Nvidia insiders dumping shares
All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.
Nvidia insiders dumping shares
All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.
PainReform Provides Year-End Business Update
See More Headlines
Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
7/19/2024
Next Earnings (Estimated)
8/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRFX
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+281.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.65 per share

Miscellaneous

Free Float
1,329,000
Market Cap
$1.07 million
Optionable
Not Optionable
Beta
0.61
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ehud Geller Ph.D.
    Executive Chairman
  • Mr. Ilan Hadar M.B.A. (Age 55)
    CEO & CFO
    Comp: $404k
  • Dr. Sigal Aviel (Age 60)
    Chief Operating Officer
    Comp: $345k
  • Prof. Eli Hazum Ph.D.
    CTO & Director
  • Ms. Rita Keynan (Age 55)
    Vice President of Pharmaceutical Operations
    Comp: $302k
  • Dr. Stephen A. Cooper D.M.D Ph.D.
    Executive Vice President of Development

PRFX Stock Analysis - Frequently Asked Questions

How have PRFX shares performed this year?

PainReform's stock was trading at $2.75 at the beginning of 2024. Since then, PRFX shares have decreased by 81.6% and is now trading at $0.5050.
View the best growth stocks for 2024 here
.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($2.72) EPS for the quarter.

When did PainReform's stock split?

PainReform shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did PainReform IPO?

PainReform (PRFX) raised $20 million in an initial public offering on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO.

How do I buy shares of PainReform?

Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX) and Cisco Systems (CSCO).

This page (NASDAQ:PRFX) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners